To get a sense of who is truly in control of Cardinal Health, Inc. (NYSE:CAH), it is important to understand the ownership ...

Citi analyst Daniel Grosslight maintained a Hold rating on Cardinal Health (CAH – Research Report) today and set a price target of $140.00. The ...

The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

A recent selloff of Neurocrine Biosciences stock feels unwarranted and may have created a contrarian buy opportunity. Learn ...

We recently published a list of Jim Cramer is Bullish on These 10 Stocks. In this article, we are going to take a look at ...

A mighty gust of wind on a dreary morning only lifted the sail of the freshly cut ribbon, on Community Action House’s new set ...

A physician survey for Neurocrine Biosciences Inc's NBIX +1.72% Get Free Report Crenessity suggests "strong uptake across all patient segments," according to Needham. The Neurocrine Biosciences ...

In a report released today, Erin Wright from Morgan Stanley maintained a Buy rating on Cardinal Health (CAH – Research Report), with a price ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could ...

Cardinal Health Inc. closed 5.54% short of its 52-week high of $139.50, which the company achieved on April 3rd.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...